Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 12

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

365

HTML

2997

Figures (1-2)

255

Tables (1-6)

220

Sum=3837

Mar 28, 2012 (publication date) through Nov 24, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Mar 28, 2012; 18(12): 1357-1364
Published online Mar 28, 2012. doi: 10.3748/wjg.v18.i12.1357

Table 6 Dose reduction n (%)

Dose reduction	Patients
Neutropenia grade 2 or 3-4	5 (6.2)
Thrombocytopenia grade 2	4 (5.0)
Hand-foot skin reaction grade 2	5 (6.2)
Neuropathy grade 2	2 (2.4)
Diarrhea grade 3-4	1 (1.2)

Citation: Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, Assenat E. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol 2012; 18(12): 1357-1364
URL: https://www.wjgnet.com/1007-9327/full/v18/i12/1357.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i12.1357